Bokemeyer S, Haense C, Geworski L, Bengel FM, Müller-Vahl K. Evidence for an involvement and therapeutic relevance of the serotonergic system in Tourette syndrome with co-morbidities. Tagung der Europäischen

2020 DOI: 10.1038/s41523-020-0168-9 Stahl K, Bode C, David S. First do no harm-beware the risk of therapeutic plasma exchange in severe COVID-19. Crit Care 2020;24(1):363-020-03070-7 DOI: 10.1186/s13054-0 [...] A, Ranjbar E, Jahromi M, Seyedebrahimi R, Skripuletz T, Moharrami Kasmaie F. The Immunological Therapeutic Strategies for Controlling Multiple Sclerosis: Considerations during the COVID-19 Pandemic. Bi [...] SARS-CoV-2 Omicron sublineages show comparable cell entry but differential neutralization by therapeutic antibodies. Cell Host Microbe 2022 DOI: 10.1016/j.chom.2022.04.017 Siegerist F, Hay E, Dikou JS

Acad Sci U S A. 2012 Apr 17. [Epub ahead of print] PubMed PMID: 22511722. Prinz I, Koenecke C. ; Therapeutic potential of induced and natural FoxP3+ regulatory T cells for the treatment of graft-versus-host

Human synaptotagmin-II is not a high affinity receptor for botulinum neurotoxin B and G: increased therapeutic dosage and immunogenicity. FEBS Lett. 2012 Feb 17;586(4):310-3 Willjes G , Mahrhold S, Strotmeier

, Middendorff, R., Loveland, K.L., Hedger, M.P., Meinhardt, A. (2019). Dexamethasone improves therapeutic outcomes in a preclinical bacterial epididymitis mouse model. Hum. Reprod. 34, 1195-1205. Scharf

Rasmussen BB, Lokau J, Lenk L, Garbers C, Feuerhake F , Rose-John S, Waetzig GH, Rosenstiel P. Therapeutic Interleukin-6 Trans-signaling Inhibition by Olamkicept (sgp130Fc) in Patients With Active Inflammatory

Explored as Potential Treatment Option in Diabetic Retinopathy: Clinical Concept and Methodology.” Therapeutic Advances in Endocrinology and Metabolism 10:204201881989188. doi: 10.1177/2042018819891886. Trudzinski

R., Koenecke, C., & Schultze-Florey, C. R. (2022). Spectral flow cytometry cluster analysis of therapeutic donor lymphocyte infusions identifies T cell subsets associated with outcome in patients with AML

Langhof H, Chin WWL, Wieschowski S, Federico C, Kimmelman J, Strech D. Preclinical efficacy in therapeutic area guidelines from the U.S. Food and Drug Administration and the European Medicines Agency: a